ContegoDerm: Topical cream to prevent radiation dermatitis


Peter Wipf, PhD Scientific Co-PI
Professor of Chemistry
Co-Leader, Molecular Therapeutics Program, UPCI
Email:WipfAdmin@pitt.edu
(412) 624-8606
http://ccc.chem.pitt.edu/wipf/Peter_Wipf.html
Louis D. Falo, Jr., MD, PhD Clinical Co-PI
Chairman, Department of Dermatology
Professor of Dermatology & Bioengineering
Email:lof2@pitt.edu
(412) 864-3760
http://www.mirm.pitt.edu/our-people/faculty-staff-bios/louis-d-falo-jr-md-phd/

Radiation dermatitis affects over four million cancer patients in the US. In addition to discomfort and lowering the quality of life, this disease also negatively affects cancer treatment compliance. Radiation-induced skin damage results from increased mitochondrial ROS (reactive oxygen species) and causes redness, swelling, blistering, and/or itchy skin. Currently, only symptomatic treatments exist for managing radiation dermatitis; there are no curative or preventative treatments options available to the patients. ContegoDerm is a topical cream with antioxidant properties that has been shown to significantly reduce the clinical manifestations of radiation-induced skin damage when applied either before or immediately after radiation exposure in pre-clinical studies.